Bg pattern

ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

ALTUVOCT 250 IU powder and solvent for solution for injection

ALTUVOCT 500 IU powder and solvent for solution for injection

ALTUVOCT 750 IU powder and solvent for solution for injection

ALTUVOCT 1,000 IU powder and solvent for solution for injection

ALTUVOCT 2,000 IU powder and solvent for solution for injection

ALTUVOCT 3,000 IU powder and solvent for solution for injection

ALTUVOCT 4,000 IU powder and solvent for solution for injection

efanesoctocog alfa (recombinant human coagulation factor VIII)

This medicinal product is subject to additional monitoring, which will allow for the quick identification of new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is ALTUVOCT and what is it used for
  2. What you need to know before you use ALTUVOCT
  3. How to use ALTUVOCT
  4. Possible side effects
  5. Storage of ALTUVOCT
  6. Contents of the pack and further information

1. What is ALTUVOCT and what is it used for

ALTUVOCT contains the active substance efanesoctocog alfa, a factor VIII replacement protein.

ALTUVOCT is used to treat and prevent bleeding episodes in patients with haemophilia A (a hereditary bleeding disorder caused by a deficiency of factor VIII) and can be used in patients of all age groups.

Factor VIII is a protein that is naturally present in the body and is necessary for blood to clot and stop bleeding. In patients with haemophilia A, factor VIII is absent or does not work properly.

ALTUVOCT replaces this deficient or absent factor VIII. ALTUVOCT increases factor VIII levels in the blood, helping the blood to form clots at the site of bleeding, which temporarily corrects the tendency to bleed.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use ALTUVOCT

Do not use ALTUVOCT

  • if you are allergic to efanesoctocog alfa or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor, pharmacist, or nurse before starting treatment with ALTUVOCT.

  • There is a rare possibility that you may experience an anaphylactic reaction (a severe and sudden allergic reaction) to ALTUVOCT. Signs of allergic reactions include generalised itching, hives, feeling of chest tightness, difficulty breathing, and low blood pressure. If any of these symptoms occur, stop the injection immediately and contact your doctor.
  • Consult your doctor if you think you are not getting control of your bleeding or your child's bleeding with the dose you are receiving, as there may be several reasons for this. In some people using this medicine, antibodies against factor VIII (also known as factor VIII inhibitors) may develop. The formation of factor VIII inhibitors is a known complication that can occur during treatment with all factor VIII medicines. These inhibitors, especially at high levels, prevent the treatment from working properly; you or your child will be closely monitored for the development of these inhibitors.

Cardiovascular events

If you have heart disease or are at risk of heart disease, be careful when using factor VIII medicines and consult your doctor.

Catheter-related complications

If you need a central venous access device (CVAD), consider the risk of CVAD-related complications, including local infections, bacteria in the blood, and thrombosis at the catheter insertion site.

Other medicines and ALTUVOCT

Tell your doctor if you are using, have recently used, or might use any other medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.

Driving and using machines

ALTUVOCT has no or negligible influence on the ability to drive and use machines.

3. How to use ALTUVOCT

Treatment with ALTUVOCT will be started by a doctor experienced in the care of patients with haemophilia A. ALTUVOCT is administered by injection into a vein.

After receiving the necessary training in the correct injection technique, patients or caregivers can administer ALTUVOCT at home. Your doctor will calculate your dose (in international units [IU]). This will depend on your weight and whether it is used for prevention or treatment of bleeding.

Follow your doctor's instructions for administering this medicine exactly. If you are unsure, consult your doctor, pharmacist, or nurse again.

Keep a record

Each time you use ALTUVOCT, note the date, the name of the medicine, and the batch number.

Prevention of bleeding

The usual dose of ALTUVOCT is 50 international units (IU) per kilogram of body weight. The injection is administered once a week.

Treatment of bleeding

The dose of ALTUVOCT is 50 international units (IU) per kilogram of body weight. The dose and frequency may be adjusted based on the severity and location of the bleeding.

Use in children and adolescents

ALTUVOCT can be used in children of all ages; the dosing recommendation is the same as for adults.

How to administer ALTUVOCT

ALTUVOCT is administered by injection into a vein. See "Instructions on how to use ALTUVOCT" for more information.

If you use more ALTUVOCT than you should

Inform your doctor as soon as possible. Follow your doctor's instructions for administering ALTUVOCT exactly. If you are unsure, consult your doctor, pharmacist, or nurse again.

If you forget to use ALTUVOCT

Do not inject a double dose to make up for forgotten doses. Inject your dose as soon as you remember and then resume your normal dosing schedule. If you are unsure, consult your doctor, pharmacist, or nurse.

If you stop treatment with ALTUVOCT

If you stop treatment with ALTUVOCT, you may no longer be protected against bleeding or an existing bleed may not stop. Do not stop treatment with ALTUVOCT without consulting your doctor.

If you have any further questions on the use of this medicine, ask your doctor.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If an anaphylactic reaction occurs, the injection should be stopped immediately and your doctor should be contacted immediately.

Symptoms of an anaphylactic reaction include:

  • facial swelling
  • rash
  • generalised itching
  • hives
  • feeling of chest tightness
  • difficulty breathing
  • burning and stinging at the injection site
  • chills
  • flushing
  • headache
  • low blood pressure
  • general feeling of being unwell
  • nausea
  • agitation and rapid heartbeat
  • feeling of dizziness
  • loss of consciousness

Risk of inhibitor formation

In children who have not received prior treatment with factor VIII medicines, the formation of inhibitory antibodies (see section 2) is very common (may affect more than 1 in 10 patients); however, in patients who have received prior treatment with factor VIII (more than 150 days of treatment), the risk is uncommon (may affect up to 1 in 100 patients). If you or your child develop inhibitory antibodies, the medicine may stop working properly and you or your child may experience persistent bleeding. If this happens, contact your doctor immediately.

The following side effects may occur with this medicine.

Very common side effects (may affect more than 1 in 10 people)

  • headache
  • arthralgia (joint pain)

Common side effects (may affect up to 1 in 10 people)

  • pain in the limbs (arms, hands, legs, or feet)
  • back pain
  • eczema (itching, redness, or dryness of the skin)
  • rash
  • urticaria (itchy rash)
  • fever
  • vomiting

Uncommon side effects (may affect up to 1 in 100 people)

  • reactions at the injection site (including bruising and inflammation)

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of ALTUVOCT

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial after "EXP". The expiry date refers to the last day of the month stated.

Store in a refrigerator (between 2°C and 8°C).

Do not freeze.

Keep the vial in the outer packaging to protect it from light.

Before reconstitution, the ALTUVOCT powder can be stored at room temperature (≤ 30°C) for a single period not exceeding 6 months. The date of removal from the refrigerator should be noted on the carton. After storage at room temperature, the medicine should not be returned to the refrigerator.

The medicine should not be used after the expiry date printed on the vial or 6 months after removal from the refrigerator, whichever is the earlier.

Once the ALTUVOCT powder has been dissolved in the solvent provided in the pre-filled syringe, it should be used immediately. Do not refrigerate the prepared solution.

After reconstitution, the solution should be clear and colourless to slightly opalescent. Do not use this medicine if you notice it is cloudy or contains visible particles.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Content and Additional Information

ALTUVOCT Composition

  • The active ingredient is efanesoctocog alfa (recombinant human coagulation factor VIII).

Each ALTUVOCT vial nominally contains 250, 500, 750, 1,000, 2,000, 3,000, or 4,000 IU of efanesoctocog alfa.

  • The other components are sucrose, calcium chloride dihydrate, histidine, arginine hydrochloride, and polysorbate 80.

Product Appearance and Container Content

ALTUVOCT is presented as a powder and solvent for solution for injection. The powder is a loose or compact powder of white to off-white color. The solvent supplied for preparation of the solution for injection is a clear and colorless solution. After preparation, the solution for injection is clear and colorless to slightly opalescent.

Each ALTUVOCT container contains 1 vial of powder, 3 ml of solvent in a pre-filled syringe, 1 plunger rod, 1 vial adapter, and 1 infusion set.

Marketing Authorization Holder and Manufacturer

Swedish Orphan Biovitrum AB (publ)

SE-112 76 Stockholm

Sweden

Swedish Orphan Biovitrum AB (publ)

Norra Stationsgatan 93

113 64 Stockholm

Sweden

Date of Last Revision of this Leaflet:

Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.

Turn the leaflet over to see instructions for preparation and administration of the medicinal product.

Instructions on How to Use ALTUVOCT

READ THESE INSTRUCTIONS CAREFULLY BEFORE USING ALTUVOCT

ALTUVOCT is administered by intravenous injection after dissolving the injectable powder with the solvent supplied in the pre-filled syringe.

If your dose requires more than one vial, you will receive several containers and, ideally, a large syringe.

Your healthcare professional should teach you how to prepare and inject ALTUVOCT correctly before you use it for the first time. Ask your healthcare professional if you have any questions.

Important Information

Check that the name and dose of the medicinal product are correct and that you know the frequency of administration of ALTUVOCT.

Do not use the medicinal product if it has expired, been opened, or appears to be damaged.

ALTUVOCT must not be mixed with other injectable solutions.

ALTUVOCT should ideally be stored in the refrigerator. Allow the vial and solvent syringe to reach room temperature before use. Do not use external heat.

Check that none of the components are damaged before use; do not use them if they appear to be damaged.

All components are for single use only.

Wash your hands and clean a flat surface before preparing the kit. Place the syringe securely on a flat surface when not handling it.

Guide to the Components (Included in the Box)

ALTUVOCT is reconstituted by dissolving the injectable powder (A) in the solvent supplied in the pre-filled syringe (B). The ALTUVOCT solution is then administered using the infusion set (E).

Clear glass vial with black cap and small silver safety device attached to the side

Pre-filled transparent syringe with black plunger and silver needle visible inside

Silver hypodermic needle with sharp bevel and long metal cylinder for insertion into the skin

Protective cap of a vial with conical design and grooves, top view with circular edge and small central hole

Glass ampoule inside a rectangular transparent plastic blister pack

  • Powder vial

  • 3 ml syringe

(pre-filled with solvent)

  • Plunger rod

  • Vial adapter

  • Infusion set

Additional Components (Not Included in the Box)

Make sure you have alcohol swabs (F).

You may have been provided with a large syringe (G) by your pharmacist to withdraw the solution from several vials into a single syringe. If you have NOT been provided with a large syringe, follow steps 6 to 8 to administer the solution from each syringe.

Rectangular packages stacked showing individual packaging of a medicinal product or medical device

Transparent syringe with metal plunger and graduated numerical scale to measure liquid volume

  • Alcohol swabs
  • Large syringe

Reconstitution

  1. Prepare the Vial
  1. Remove the Vial Cap

Hold the powder vial (A) over a clean and flat surface and remove the

plastic cap.

Index finger pressing the top of a hypodermic needle inserted into the skin at a right angle

  1. Clean the Vial Top

Clean the top of the vial with an alcohol swab.

Make sure nothing comes into contact with the top of the vial once it has been cleaned.

Vial of medicinal product with gray cap and hand holding a needle over the cap to withdraw the liquid

  1. Open the Vial Adapter Package

Remove the paper protective cap from the vial adapter package (D).

Do not touch the vial adapter or remove it from its package.

Needle inserted into the skin with a rectangular applicator device and lines indicating the direction of injection

  1. Attach the Vial Adapter

Place the vial adapter package directly over the top of the vial.

Press firmly downwards until the adapter is in place. The spike will puncture the vial stopper.

Vial of medicinal product with stopper and syringe pressing downwards to withdraw the liquid with an arrow indicating the direction

  1. Prepare the Syringe
  1. Attach the Plunger Rod

Insert the plunger rod (C) into the 3 ml syringe (B). Turn the

plunger rod clockwise until it is securely attached.

Medical device with transparent cylinder, black plunger, and flexible tube connection with cross-shaped connector

  1. Remove the Syringe Cap

Separate the top part of the syringe cap from the 3 ml syringe by the

perforations and set it aside.

Do not touch the inside of the syringe cap or the tip of the

syringe.

Hand holding an auto-injector with the protective cap removed showing the plunger and exposed needle

  1. Attach the Syringe to the Vial
  1. Remove the Vial Adapter Package

Lift the package to separate it from the vial adapter and discard it.

Vial of medicinal product with attached adapter and hand holding a needle at an angle for withdrawal

  1. Attach the Syringe to the Vial Adapter

Hold the vial adapter by the lower end. Place the tip of the syringe over

the top of the vial adapter. Turn the syringe clockwise until it is securely attached.

Hands holding an auto-injector with exposed needle pointing towards a transparent medicinal product vial

  1. Dissolve the Powder and Solvent
  1. Add the Solvent to the Vial

Slowly press the plunger rod to inject all the solvent into the vial.

Transparent syringe with black plunger showing arrows indicating direction of injection and filling

  1. Dissolve the Powder

Gently swirl the vial in a circular motion with your thumb over the

plunger rod until the powder is dissolved.

Do not shake.

Needle connected to a cylinder with spiral, curved arrows indicating rotation for insertion or removal of the device

  1. Inspect the Solution

Inspect the solution before administration. It should be clear and colorless.

Do not use the solution if it is cloudy or contains visible particles.

  1. If Using More Than One Vial

If your dose requires more than one vial, follow the steps below (5a and 5b); otherwise, proceed to step 6.

  1. Repeat Steps 1 to 4

Repeat steps 1 to 4 with all vials until you have prepared enough solution for your dose.

Remove the 3 ml syringes from each vial (see step 6b), leaving the

solution in each vial.

Needle inserted into a cartridge with a protective cap, showing rotation direction and three additional cartridges

  1. Using a Large Syringe (G)

For each vial, attach the large syringe (G) to the vial adapter (see

step 3b) and perform step 6 to combine the solution from each vial into the large syringe. If you only need part of a whole vial, use the graduated scale on the syringe to see the amount of solution you are withdrawing, as instructed by your healthcare professional.

Hand holding a vial of medicinal product with a needle connected to an adapter for withdrawal

  1. Withdraw the Solution into the Syringe
  1. Withdraw the Solution

Hold the syringe upright. Slowly pull the plunger rod to transfer all the

solution into the syringe.

Hand holding an injection device with exposed needle and arrow indicating direction of insertion

  1. Detach the Syringe

Detach the syringe from the vial by holding the vial adapter. Turn the

syringe counter-clockwise to detach it.

Auto-injector device with inserted cartridge and arrow indicating rotation to activate the dose in the arm

Administration

  1. Prepare for Injection
  1. Remove the Tube Cap

Open the infusion set package (E) (do not use if it is damaged).

Remove the tube cap.

Do not touch the exposed end of the tube.

Hypodermic needle inserted into the skin at an angle with a safety device activated over the needle

  1. Attach the Syringe

Attach the prepared syringe to the end of the infusion set tube by turning

the syringe clockwise.

Applicator device with needle inserted into the skin, curved arrow indicating rotation, and detached part showing the plunger

  1. Prepare the Injection Site

If necessary, apply a tourniquet. Clean the injection site with an alcohol

swab (F).

Hand with glove applying a medicinal patch to the skin on the back of another gloved hand

  1. Remove Air from the Syringe and Tube

Remove air by holding the syringe upright and gently pressing the

plunger rod. Do not push the solution through the needle.

Air injection into a vein can be hazardous.

Syringe connected to a catheter inserted under the skin with a black arrow indicating the direction of insertion

  1. Inject the Solution
  1. Insert the Needle

Remove the needle protective cap.

Insert the needle into a vein, as instructed by your doctor or nurse, and

remove the tourniquet if applied.

You can use a plaster to hold the plastic wings of the needle in place at the

injection site to prevent it from moving.

  1. Inject the Solution

The prepared solution should be injected intravenously over 1 to 10 minutes, depending on the patient's comfort level.

  1. Dispose of the Material Safely
  1. Remove the Needle

Remove the needle. Fold the needle protector; it should click into

place.

Applicator device with needle inserted into the skin, showing the direction of sliding and release

  1. Safe Disposal

Dispose of the used needle, any unused solution, the syringe, and the empty vial safely in an appropriate medical waste container.

Do not reuse the equipment.

Online doctors for ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Discuss questions about ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
The active ingredient in ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION is coagulation factor VIII. This information helps identify medicines with the same composition but different brand names.
Who manufactures ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION is manufactured by Swedish Orphan Biovitrum Ab (Publ). Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to ALTUVOCT 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
Other medicines with the same active substance (coagulation factor VIII) include ADVATE 1,000 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION, ADVATE 1500 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION, ADVATE 1000 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media